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Malaria-causing Plasmodium parasites are deposited into host skin as infected 
Anopheles mosquitoes search for blood. In order for Plasmodium to establish infection in 
the liver, sporozoites need to exit the inoculation site, which they do by moving in the 
skin to find blood vessels and enter the circulation. This stage of the Plasmodium 
lifecycle (the pre-erythrocytic stage), at which parasite numbers are the lowest, has been 
recognized as a bottleneck for the parasite. RTS,S, the only vaccine candidate to have 
shown efficacy in Phase III clinical trials, targets the pre-erythrocytic stages of the 
parasite. Indeed further studies have shown that antibodies targeting the major surface 
protein of sporozoites (circumsporozoite protein or CSP) are critical for RTS,S-mediated 
immunity. We hypothesized that since sporozoites are extracellular for a significant 
period of time at the inoculation site, antibodies in the skin could contribute significantly 
to decreasing sporozoite infectivity. Using rodent malaria parasite Plasmodium berghei, 
we standardized the dose of sporozoites delivered intravenously and by mosquito bite that 
result in comparable liver infection. We then compared the efficacy of two different 
doses of a monoclonal antibody (mAb) specific for the P. berghei CSP repeats (50 µg & 
25 µg mAb 3D11; IgG1) in their ability to inhibit infection when sporozoites were 
inoculated intravenously versus by mosquito bite. Our data shows that both 
concentrations of antibody have greater efficacy when sporozoites are inoculated by 
mosquito bite. These results have important implications for malaria vaccine 
development, and provide further insight into host-pathogen interactions in the skin. 
Primary Reader: Photini Sinnis, M.D. 
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Malaria Epidemiology & Control 
 
Malaria is a mosquito-borne parasitic disease that has plagued humanity for 
centuries, and continues to exert a heavy disease burden, particularly in sub-Saharan 
Africa and Southeast Asia. According to the WHO Malaria World Report 2016, there 
were about 400,000 deaths reported from malaria – most of them in children.
1
 This 
equates to roughly one child dying every three minutes. Moreover, an estimated two 




Figure 1. A schematic representation of the disease burden of malaria 2000-2016. 




The total burden of disease associated with malaria has decreased significantly 
over the past century. This has been achieved primarily through widespread use of 
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insecticide-treated bednets, mass campaigns for indoor residual spraying, and the 
availability of effective antimalarials combined with improved rapid diagnostics.
2,3
 
Although these tools have helped us gain a significant advantage in our continuing fight 
against malaria, it has become clear that eliminating, and subsequently eradicating, 
malaria will require additional tools including improved rapid diagnostics, novel 
therapeutic drugs, and effective vaccines.
4,5
 
With an integrated approach to malaria elimination, it is hoped that we will be 
able to meet WHO’s Sustainable Development Goals (SDGs) target of globally 
eliminating malaria by 2030.
6
 However, the timely attainment of this goal has recently 
been threatened by the emergence of drug-resistant malaria in the Greater Mekong Sub-
region (which includes Cambodia, the Lao People’s Democratic Republic, Myanmar, 
Thailand and Vietnam).
3
 A key tool in achieving these goals might be an effective 
malaria vaccine, preventing the establishment of infection and reducing the generation of 
drug-resistant parasites. The ensuing literature review will describe the malaria parasite 
life cycle, focusing in particular on the silent stage of infection – the pre-erythrocytic 
stage i.e. the stage of the parasite life cycle prior to clinical disease. This is followed by a 
discussion of RTS,S, arguably a milestone in malaria vaccine development but with 
considerable shortcomings and opportunities for improvement. Finally, the development 
of a novel methodology for studying the pre-erythrocytic stages of Plasmodium is 





Plasmodium lifecycle & inoculation by mosquito 
  
Malaria infection is initiated with the bite of an infected female Anopheles 
mosquito. While there are around 450 known species of Anopheles mosquitoes, only 
about 60 are capable of supporting the malaria parasite’s sexual development.
7
 Of these, 
Anopheles stephensi (Southeast Asia), Anopheles darlingi and Anopheles albimanus 
(Central & South America), and the Anopheles gambiae species complex (sub-Saharan 
Africa) are among the most important in terms of maintaining disease transmission.
8
 
These mosquitoes are capable of supporting the sexual development of the four common 
human malaria-causing Plasmodium parasites (Plasmodium falciparum, vivax, ovale, 
malariae). Plasmodium falciparum is responsible for the largest burden of lethal 
infections in the world, and is the primary focus of vaccine and drug development.
1
 
Based on disease prevalence, Plasmodium vivax is considered to be the second most 
important human malaria parasite and has the unique ability (along with the 
geographically restricted Plasmodium ovale) to undergo dormancy in the liver.
58
 The fifth 
human malaria parasite, Plasmodium knowlesi is primarily a zoonosis reported mainly in 
Southeast Asia (Malaysian Borneo) but is lethal to humans if contracted.
9
 However, it is 
important to note it is not known if sustained human transmission of P. knowlesi occurs 
in the field; it has only been shown to be possible in an experimental setting.
10
  
Regardless of the species, all human Plasmodium parasites are introduced into the 
host skin by an infected mosquito bite. The process of bloodmeal acquisition can be 
broken down into two distinct mutually exclusive phases: probing and imbibing.
11
 During 
the probing phase, a mosquito salivates into host skin as it searches for blood to facilitate 
locating blood.
12,13
 Mosquito saliva is a complex composition of molecules with various 
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functions, including vasodilators and anticoagulants that facilitate blood meal 
acquisition.
13
 Since sporozoites reside in the salivary glands of the mosquito, it stands to 
reason that they would be inoculated while the mosquito is searching for blood 
(salivating into the skin). Indeed, several lines of evidence now show that the large 
majority of inoculated Plasmodium parasites are inoculated into the host skin – and not 
directly into circulation as was previously assumed.
14, 15, 16, 49, 57, 59
 Moreover, the total 
number of parasites inoculated by the mosquito is quite low.
49, 63
 For example, Medica & 
Sinnis estimate that the median number of sporozoites inoculated is eighteen.
49
 Of the 
inoculated sporozoites, only about 20% exit the skin, leaving over several hours in a slow 
trickle from the site of inoculation.
18, 35
 Yamauchi et al. show using the rodent parasite 
Plasmodium yoelii that most of the parasites remain in the dermis up to at least an hour 
post-inoculation.
35
 This gradual exit from the site of inoculation suggests the possibility 
of previously unappreciated interactions between Plasmodium parasites and the host 
immune system. Importantly, given the time the parasite spends in the dermis, Yamauchi 
et al reinforce the possibility that neutralizing antibodies specific to the parasite could 
play an important role in the host immune response against Plasmodium infection.
35
 
Once in the skin, the parasite must find and invade blood vessels in order to reach 
the liver, where it then establishes infection.
16
 The parasite moves in the skin using a 
substrate-dependent mechanism of motility called gliding motility.
17
 From the point of 
inoculation, the sporozoites initially move outwardly in relatively linear trajectories. 
After some time, there is a noticeable change in sporozoite motility patterns, with their 
movement becoming more circular.
18
 This constrained movement is particularly seen 
when sporozoites are in the vicinity of blood vessels, suggesting that sporozoites are able 
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to sense their environment and alter their movement accordingly.
18
 The precise signals, if 
any, that regulate these motility patterns are not yet known. In addition, the mechanism of 
blood vessel invasion by sporozoites is also an unanswered question, but a recent study 
suggests that sporozoites might display a tropism for blood vessels with curvatures 
similar to their own.
19
 
Following the invasion of a blood vessel, Plasmodium sporozoites reach the liver 
within minutes and invade hepatocytes, crossing the liver sinusoids through either 
Kuppfer or endothelial cells.
20, 21
 After invasion, sporozoites form a parasitophorous 
vacuole and begin to differentiate and divide to give rise to tens of thousands of 
merozoites. The infected hepatocyte ruptures, and merozoites are released into the 
circulation where they invade red blood cells.
22, 23
 The erythrocytic stage of malaria 
infection is responsible for the clinical symptoms that are generally associated with 
malaria. These symptoms are commonly characterized by recurrent fevers, chills, 
headache, and nausea. It is important to note that in contrast to the symptomatic 
erythrocytic stage, the pre-erythrocytic stage has no symptoms associated with it, and is 
clinically silent.  
During the erythrocytic stage, some of the parasites differentiate into male and 
female gametocytes, which are taken up by a mosquito, differentiate into gametes which 
fuse to form an invasive ookinete which traverses the mosquito midgut epithelium, 
eventually forming an oocyst on the basal side of the mosquito midgut epithelium. It is 
within the oocyst that sporozoite development occurs. Upon rupture of the oocyst, 
sporozoites are released into the hemocoel and invade the salivary glands of the mosquito, 





Figure 2. The lifecycle of human Plasmodium parasites. The illustration 
highlights the three stages of development within the host (pre-erythrocytic stage, 
asexual erythrocytic stage, and intra-erythrocytic gametocyte stage), as well as the 
sexual stage in the mosquito vector. 






In the Plasmodium parasite’s life cycle in the host, there are two bottlenecks that 
can potentially be exploited for vaccine development (Figure 3).
5, 24
 These are the two 
transmission stages of the parasite, sporozoites and gametocytes. These bottlenecks have 
been the basis of pre-erythrocytic and transmission blocking vaccines.
5
 It is important to 
note however that whereas transmission blocking vaccines aim to reduce disease 
transmission through the mosquito, only pre-erythrocytic stage vaccines aim to prevent 
the development of malaria infection and symptomatic disease. Because of this, the pre-
erythrocytic stage was previously identified as a vaccine target, which led to the 












Figure 3. Schematic of Plasmodium parasite bottlenecks. Bottlenecks are points in 
the parasite lifecycle at which it has low numbers in the host and is, in theory, a 
vulnerable target. These bottlenecks may be exploited for malaria vaccine 
development. 
Image credit: Modified from Cowman, A.F., Healer, J., Marapana, D. and Marsh, 





Malaria Vaccine Development & RTS,S – humanity’s first malaria vaccine 
 
Malaria vaccine development has been a work in progress since the 1960s when 
radiation-attenuated sporozoites (delivered by 1000 mosquito bites) were shown to 
induce sterile protection in 100% of the volunteers when re-challenged with infected 
mosquitoes.
26
 In addition to the logistical challenges inherent in delivering a thousand 
infected bites with irradiated mosquitoes, there are additional regulatory hurdles that need 
to be considered. Hence, vaccination by irradiated mosquito bites is an unlikely 
vaccination approach for malaria. However, a number of alternative vaccine strategies 
have now been tried, including radiation attenuated whole sporozoites, genetically 
attenuated whole sporozoites, DNA-based approaches, as well as virally vectored 
strategies.
27
 The most successful candidate to date has been the subunit vaccine candidate 




RTS,S, first developed in 1987 as a collaboration between Glaxosmithkline (GSK) 
and the Walter Reed Army Institute of Research, contains part of the central repeat region 
as well as a CD4+ T-cell epitope of the major surface sporozoite antigen called the 
circumsporozoite protein (CSP) recombinantly expressed in yeast.
29
 This is then fused to 
the hepatitis B surface antigen as a carrier (Figure 4). Moreover, the vaccine is delivered 






Unfortunately, results from the recently completed Phase III clinical trials paint a 
somewhat disappointing picture. The vaccine was administered to 6-12 week olds as well 
as 5-17 month olds at 0, 1, and 2 months, with a booster dose at 18 months. Results of the 
Phase III trials show a protective efficacy of 25.9% in the 6-12 week cohort and 36.3% in 
the older cohort.
31
 In addition to the low degree of protection RTS,S elicits, the induced 
protection decreases over a year.
31
 These results fall short of meeting the 2015 goals of 
the Malaria Vaccine Technology Roadmap, according to which an effective malaria 
vaccine must provide at least 50% protection against death and severe disease for a year, 
and prevent at least 75% of clinical cases.
32
  
However, interestingly, post-trial analyses of RTS,S have provided some key 
insights. These analyses show that in the 5-17 month cohort, RTS,S appears to have been 
more protective against malaria infection from parasites with genotypes that match the 
CSP allele on which RTS,S is based.
33
 Although in the phase III trial, these matched 
parasite strains amounted to only 10% of the total parasite population, the protective 
efficacy against this strain for the 5-17 month cohort was 50.3% following vaccination 
(compared to 33.4% against the mismatched strains).
33
 Another key observation in the 
post-trial analysis of RTS,S has been the strong association between protection against 
infection and anti-CSP antibody titers.
34
 Anti-CSP antibody titers were found to be higher 
in the 5-17 month cohort (compared to the 6-12 week cohort), and could predict 
protection against clinical malaria effectively, suggesting that anti-CSP antibody titers 
can be used as an immune surrogate of protection against malaria.
34
 It is worth noting that 
anti-CSP antibodies are one part of immunity against clinical disease, which also includes 
strong CD4+ and CD8+ T-cell responses. 
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 Given the importance of antibodies targeting CSP, as the RTS,S post-trial 
analyses show, and the time the malaria parasite spends in the dermis prior to subsequent 
liver infection, it is surprising how little is known regarding the potential interactions 
between host antibodies and Plasmodium parasites in the skin. It is particularly important 
to study these interactions in the context of mosquito-based transmission of Plasmodium, 
since components of mosquito saliva may interact with the parasite to mediate the 
pathogenesis of disease as well as host immunity. Understanding parasite-antibody 
interactions in the skin could significantly contribute to an enhancement of the current 
vaccine effort, as we pursue the development of second generation malaria vaccines, 
improving the protective efficacy of RTS,S, which has been shown to partly rely on anti-
CSP antibodies. However, no robust method for studying the impact of antibodies in the 











Figure 4. A schematic of CSP and RTS,S vaccine. The vaccine contains part of 
the central repeat region of CSP, the most abundant surface antigen on the 
sporozoite surface, fused to the hepatitis B surface antigen.  
Image credit: Crompton, Peter D., Susan K. Pierce, and Louis H. Miller. 
"Advances and challenges in malaria vaccine development." The Journal of 









Established Methods for Malaria Parasite Inoculation 
 
Many of the original studies, performed in birds, rodents, and humans for 
studying malaria pathogenesis as well as vaccine development, were done using infected 
mosquito bites as the route of parasite transmission. However, a key limitation of using 
mosquitoes for inoculating parasites is that it is difficult to precisely quantitate and/or 
predict the dose of the inoculum.
35, 36
 Given these challenges, more predictable methods 
for parasite inoculation were explored. One of the earliest comparisons of the different 
routes of parasite inoculation were done with Plasmodium gallinaceum using Aedes 
mosquitoes to infect chicks.
37
 These included intravenous, intrahepatic, intramuscular, 
subcutaneous, oral, and intraperitoneal routes of parasite inoculation. Of these, 




Following the discovery of the rodent malaria parasite, Plasmodium berghei, 
intravenous methods of inoculation were regularly performed for immunizing and 
subsequently challenging rodent models with P. berghei sporozoites for studying host 
immunity against the pre-erythrocytic stages of malaria. However, at the time, it was 
supposed that mosquito inoculation of parasites mimicked intravenous inoculation of 
parasites, and the skin stage of malaria infection was largely ignored. Given the growing 
appreciation that most of the sporozoites inoculated by mosquito bite in mosquito saliva 
are inoculated into the skin and can spend several hours there, alternate routes of parasite 





A more biologically-relevant route of parasite inoculation is the intradermal route, 
with the key advantage that it attempts to mimic potential host-parasite interactions in the 
dermis.
38
 This involves dissecting mosquitoes, quantifying sporozoites, and injecting 
them in solution into the dermis of the experimental animal. Although this approach is 
much better than intravenous inoculation of parasites for studying the pre-erythrocytic 
stage of malaria infection, mechanical injections can be challenging to reproduce. This is 
in part due to the manual dexterity that is required from the experimenter. In addition, 
there is a growing body of evidence suggesting that complex interactions between 
components of mosquito saliva and a pathogen may enhance disease pathogenesis.
39, 40, 41, 
42, 43
 Consequently, there has been an increasing appreciation of parasite inoculation by 
mosquito, and a more standardized method of studying host immunity against the pre-
erythrocytic stage is needed.  
Using the rodent malaria model, Plasmodium berghei, the following work will 
establish a mosquito bite challenge model (normalized to the liver parasite burden) as an 
alternative to intradermal methods of parasite inoculation for studying the pre-
erythrocytic stage of the malaria parasite. We then use this model to compare the 
protective efficacy of two different doses of an antibody targeting P. berghei sporozoites 
using intravenous and mosquito bite routes of parasite inoculation. Specifically, we test 
the hypothesis that antibodies targeting the malaria parasite have greater efficacy against 
parasites delivered via mosquito bite due to the fact that the parasite is extracellular for 
the longest period in the skin. We anticipate this work will have implications for future 





Source of Animals 
 
Female C57BL/6J mice were purchased from Taconic Farms (Derwood, MD), 
and housed in the animal facility at the Johns Hopkins Bloomberg School of Public 
Health. The age of the mice ranged from 5-8 weeks. The animal work presented in this 
thesis was done in accordance with the Animal Care and Use Committee (ACUC) 
guidelines (Protocol #M014H363). The Johns Hopkins University ACUC is fully 
accredited by the Association for the Assessment and Accreditation of Laboratory 
Animal Care. 
 
Methods for determining infectivity of mosquitoes 
 
Anopheles stephensi mosquitoes were reared in the insectary at the Johns Hopkins 
Bloomberg School of Public Health (Baltimore, MD). Prevalence of infection in the cage 
was determined on Day 18-21 post-infectious blood meal by microscopically examining 
the salivary glands from at least 20 female mosquitoes for the presence of sporozoites 
after applying manual pressure to rupture the gland.  
To determine the average sporozoite load in the mosquitoes, at least 10 Anopheles 
stephensi females were dissected in ice-cold Leibovitz’s L-15 medium (#11415064, 
Thermo Fisher Scientific) Dissected glands were transferred to a pre-chilled 1.5 mL 
Axygen Maximum Recovery tube (#MCT-175-L-C, Axygen Scientific) with 150 µL L-
15 medium. The glands were centrifuged (4°C) for a few seconds, homogenized 
manually using a plastic tissue grinder (#PES15BSI, Axygen Scientific), and left on ice 
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for 5 minutes. A 1:10 dilution was prepared from the sporozoite solution, and the 
sporozoites counted using a hemocytometer. For mosquito bite experiments, mosquitoes 
were only used if the average sporozoite load per mosquito was greater than 10,000 
sporozoites and the mosquito cage had a prevalence of infection of 90% or greater. 
 
Mosquito bite challenge experiments 
 
        Female mosquitoes were aspirated by mouth in batches of 25-30 mosquitoes to 
prevent potential mechanical damage caused by overcrowding in the aspirator tube. The 
mosquitoes were anesthetized on ice and gently transferred to a pre-chilled glass petri 
dish. Using forceps that were padded at the tip with tape (to prevent mechanical damage), 
the mosquitoes were lifted by the leg and transferred to plastic tubes (50 mL Falcon, 
Corning Life Sciences) with a screw cap at one end and net at the other. No more than 
four mosquitoes were placed in a single tube. The mosquito containers were then placed 
in the growth chamber (net-side up) and supplied with water to prevent death by 
dehydration. Around 6h prior to mosquito bite challenge, the water was removed. 
        Female C57BL/6J mice were anesthetized with intraperitoneal injection of 
ketamine (35-100 μg/g body weight) and xylazine-hydrochloride (6-15 μg/g body weight) 
and placed on a warming plate set to 37°C. This was done to prevent a drop in body 
temperature of the mice to facilitate mosquito bites. After gently blowing on the 
mosquitoes (to activate their host-seeking response by carbon dioxide), the containers 
were gently pushed up against the mouse ear (Figure 5). A timer was set to three minutes 
and the mosquitoes in the container were observed carefully. Once mosquitoes land on 
the ear, they probe a variable number of times before initiating blood feeding (personal 
17 
 
observation). Following observation of the desired number of mosquito bites, the mice 
were labeled and gently placed into a new mouse cage. Unless otherwise indicated, each 
ear was exposed to 4-5 mosquito bites. 
 
 
Figure 5. The mosquito bite challenge set-up. Four female Anopheles stephensi 
mosquitoes in a tube can be seen feeding on the ear of a C57BL/6J female 
(anesthetized with K/X and its body temperature regulated using a heating block 
set to 37°C). Each container of mosquitoes was allowed 3 minutes, and the 
number of mosquito bites within that time period observed. The total number of 
mosquito bites were distributed over both ears, with an approximately equal 





RNA Extraction & cDNA Synthesis 
 
40 hours after parasite challenge, mice were anesthetized with 150 µL K/X and 
sacrificed using cervical dislocation. The livers were dissected, washed twice in cold PBS 
(1X, pH 7.4), dried over kimwipes, weighed, and homogenized in 10 mL of Tri-Reagent 
(Molecular Research Center, Inc., Cincinnati, OH), using a manual homogenizer 
(Kinematica, Bohemia, NY) for 1 minute at full speed. The homogenates were allowed to 
sit at room temperature for 30 minutes and then 1 mL of the homogenate added to 200 µL 
chloroform. Following vortexing for 15 seconds, the samples were allowed to sit at RT 
for 15 min, and centrifuged for 15 minutes at 12,000 x g (4°C). 450 µL of the aqueous 
phase was added to an equal volume of Isopropanol and vortexed for 10s. After a 10 
minute incubation at room temperature, the samples were centrifuged at 15,000 x g for 10 
minutes. The pellet was washed with 70% ethanol, air dried for 5 minutes, and incubated 
in 200 µL of DEPC-treated water at 43°C for 1 hour. Standard RNA solutions (1µg/µL) 
were prepared and stored at -80°C. 
Reverse transcription was done using 1.5 µg total RNA and random hexamers as 
according to manufacturer’s instructions. The cycling profile was 25°C (10 min), 42°C 
(20 min), 95°C (5 min), and 5°C (5 min). 
 
Quantification of Parasite Liver Burden by RT-qPCR 
 
The protocol for quantifying P. berghei 18s rRNA in mouse liver is well-





Primers used for amplifying the P. berghei 18s rRNA gene were first described by 
Kumar et al.
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P. berghei 18s rRNA copy numbers were calculated based on a standard curve 












) of the P. berghei 
18s rRNA gene. 
 
Antibody Clearance: Serum Collection & ELISA 
 
50 µg mAb 3D11 was intravenously administered to 8 week old female mice. 
Approximately 50 µL of blood were collected by retro-orbital plexus under anesthesia 
(90 mg/kg ketamine and 10 mg/kg xylazine) at 6h, 12h, 18h, 24h, 48h, 72h, and 96h 
following antibody inoculation. Serum was isolated by centrifuging each blood sample at 
2000 x g for 10 minutes (4°C), and the supernatant saved. Serum samples were stored at -
20°C. 
The serum antibody levels at each point were measured by ELISA. Briefly, 96-
well plates (ThermoFisher Scientific, #3455) were coated overnight (4°C) with 1.0 
µg/mL of synthetic P. berghei CSP repeat peptide. The following day, the wells were 
washed 3x with Wash Buffer (0.05% Tween 20/PBS) and blocked with Blocking Buffer 
(2% BSA/0.05% Tween 20/PBS) for 1 hour at 37°C. Serial dilutions (1:50, 1:100, 1:200, 
1:400, 1:800, 1:1600) were prepared for each serum sample in Primary Antibody Dilution 
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Buffer (2% BSA/0.05% Tween 20/PBS). Following a 3x wash, the wells were incubated 
with primary antibody for 1 hour at 37°C. The wells were washed again 3x and incubated 
with goat anti-mouse HRP-conjugated secondary antibody (KPL, #074-1806) diluted 
1:2000 in Secondary Antibody Dilution Buffer (2% BSA/0.05% Tween 20/PBS) for 1 
hour at 37°C. Following a 3x wash with Wash Buffer and 2x wash with PBS (1X, pH 
7.4), the plates were developed using a commercially available kit (KPL, #50-62-00) for 
5 min and the absorbance measured at 405 nm. 
 
Immunofluorescence Assay (IFA) 
 
In order to characterize functionality of the purified antibody, an 
immunofluorescent assay was performed. Briefly, 10 female Anopheles stephensi 
mosquitoes were dissected 20 days post-infectious bloodmeal and the isolated sporozoites 
quantified. Wells on a Teflon/Poly-L-lysine slide (TEKDON Inc., #117-051-122) were 
coated with 10,000 sporozoites per well and left overnight at RT to air-dry. The following 
day, the wells were incubated with 4% PFA (Electron Microscopy Sciences, #15710) for 
1 hour at RT to fix the sporozoites. Following a 3x wash with PBS (1X, pH 7.4), the 
wells were blocked with 1% BSA/PBS for 1 hour at RT. The wells were washed again 3x 
with PBS (1X, pH 7.4), and incubated for 1 hour at RT with serial dilutions (0.1 µg/mL, 
0.01 µg/mL, and 0.001 µg/mL) of old and new mAb 3D11. Following another 3x wash 
with PBS (1X, pH 7.4), the wells were incubated with Rabbit anti-mouse IgG (H+L) 
ross-adsorbed secondary antibody (Thermo Fisher Scientific, #A-11062) for 1 hour at RT. 
After a final 3x wash with PBS (1X, pH 7.4), the slide was air dried for 15 minutes and 
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mounted with Prolong Gold antifade with DAPI (Thermo Fisher Scientific, #P36935). A 
cover glass was placed over the slide and left overnight to dry in the dark. 
Statistical Analyses 
 
For determining the clearance kinetics of 50 µg mAb 3D11, serial dilutions of 
each serum sample were prepared in order to normalize across all samples. This is done 
by generating a standard curve for each sample and interpolating the serum dilution that 
corresponds to an absorbance measurement of 1.0 (a point at which the concentration of 
the antibody in the serum is directly proportional to the absorbance). These interpolated 
values can be plotted against time to observe the change in serum antibody levels over 
time. 
For the comparison of liver parasite burden between groups, non-parametric 












Comparison of Intravenous versus Mosquito Bite Inoculation of Sporozoites 
 
Previous work in the Sinnis laboratory (Kim Wang & Photini Sinnis, unpublished) 
compared the efficacy of passively administered mAb 3D11 (antibody specific to P. 
berghei CSP repeats) against intravenous and intradermal routes of parasite inoculation. 
The results suggested that 50 µg of antibody administered approximately 24 hours prior 
to parasite challenge was more protective against liver infection when sporozoites were 
inoculated intradermally compared to intravenously inoculated parasites. Despite the 
greater control intradermal inoculation has afforded, it is not the natural route of pathogen 
transmission. 
Therefore, the first aim of my thesis work was to develop a mosquito bite 
challenge model using Anopheles stephensi mosquitoes and the rodent malaria parasite P. 
berghei, controlling for the number of mosquito bites per mouse as a more biologically 
relevant alternative measure of exposure to malaria parasites. For the purposes of 
standardization between intravenous and mosquito bite inoculation of parasites, we used 
the parasite liver burden as measured by RT-qPCR as an endpoint. Briefly, mice were 
challenged either intravenously with a predetermined number of sporozoites or exposed 
to a predetermined number of mosquito bites. Forty hours later, the parasite burden as a 
function of the gene copy number of P. berghei 18s rRNA in the mouse liver was 
quantified. Since there is a scarcity of published literature comparing parasite liver 
burden from different doses of sporozoites inoculated by various routes, and because 
sporozoite infectivity may vary from one laboratory to another, we first did a dose-
response curve of parasites inoculated intravenously to get a general understanding of the 
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relationship between liver parasite burden and sporozoite dose after IV inoculation.  As 
shown in Figure 6, we inoculated groups of mice with 250, 2500, 5000, and 10,000 
sporozoites and found a linear trend between the number of sporozoites inoculated IV 




















Figure 6. Liver parasite burden in groups of female C57BL/6 mice inoculated 
intravenously with 250, 2500, 5000, or 10,000 P. berghei sporozoites (n=5 
mice/group). Livers were harvested 40 hrs after sporozoite inoculation, RNA 









Similarly, in order to acquire a general understanding of the relationship between 
liver parasite burden and parasites inoculated by mosquito bite, we exposed groups of 
mice to 4, 8, or 16 mosquito bites divided over both ears (Figure 7A). In contrast to the 
linear trend we saw with increasing doses of IV inoculated sporozoites, we found no 
statistically significant difference in parasite liver burden between mice administered 8 
versus 16 mosquito bites. To determine if the saturation we were observing was 
potentially real or a function of excessive hemorrhaging in the ear following 16 mosquito 
bites, we repeated the experiment and divided the 16 mosquito bites over both ears, the 
nose, and the tail (Figure 7B). Again, we observed the same result. Given these data, we 











Figure 7A. Liver parasite burden in groups of female C57BL/6 mice exposed to 4 
(one ear), 8 (both ears), or 16 mosquito bites (both ears) (n=5 mice/group). B. 
Liver parasite burden in groups of female C57BL/6 mice exposed to 4 (one ear), 8 
(both ears), or 16 mosquito bites (bites divided over both ears, nose, and tail) (n=4 
mice/group). Livers were harvested 40 hrs after sporozoite inoculation, RNA 













, we decided to do a second intravenous titration experiment to get 
better estimates of the liver parasite burden for a narrower range of sporozoites, that more 
closely matched the liver parasite burden for 8 mosquito bites. In this experiment, we 
inoculated groups of mice with 540, 900, 1500, and 2500 P. berghei sporozoites IV, and 
included a reference group that was exposed to 8 mosquito bites (Figure 8). We found 
that the liver parasite burden in our mosquito bite reference group most closely 
















Figure 8. Liver parasite burden in groups of female C57BL/6 mice intravenously 
(I.V.) inoculated with 540, 900, 1500, or 2500 sporozoites. A group of mice 
exposed to 8 mosquito bites (M.B.) was included as reference. Mice were 
sacrificed 40 hours after challenge and liver parasite burden quantified by RT-
qPCR. n=5 mice/group for all groups except the group receiving 2500 sporozoites 







In summary, these experiments suggest that in the P. berghei ANKA system, 8 
infected mosquito bites results in a liver parasite burden equivalent to 500 intravenously 
inoculated sporozoites.  
 
Serum Clearance Kinetics of 50 µg mAb 3D11 
   
Before we could compare the efficacy of antibodies targeting sporozoites after 
inoculation by mosquito bite versus intravenously, we also needed to determine the 
optimal time for challenging mice following antibody administration. To do this, we 
investigated how the level of mAb 3D11 in the serum changes over time. We inoculated 
four female C57BL/6 mice with 50 µg mAb 3D11, took blood samples at  6h, 12h, 18h, 
24h, 48h, 72h, and 96h after mAb inoculation and determined the serum level of mAb 
3D11 of each mouse by ELISA. The results shown in Figure 9 are the average of the 
clearance kinetics in four mice. In general, we see that the level of mAb 3D11 in the 
serum follows a biphasic decay, declining sharply over the first 24 hours, and then 
declining more stably over the next three days. After 24 hours, the serum level of mAb 
3D11 was reduced by 39% compared to its level at the earliest 6h time point. 
Furthermore, from 24h to 48h, 48h to 72h, and 72h to 96h, the serum level of mAb 
declined by 15%, 11%, and 14% respectively. Based on the serum clearance kinetics, we 
chose to challenge mice 24 hours following antibody administration, as that was the point 






Figure 9. Average serum clearance kinetics of 50 µg mAb 3D11 in female 
C57BL/6 mice (n=4) over 96 hours. One serum sample from each mouse was 
collected at 6h, 12h, 18h, 24h, 48h, 72h, and 96h. Using ELISA, a standard curve 
for each serum sample was prepared by serial dilution (each dilution run in 
duplicate) to interpolate the serum dilution that corresponded to an absorbance 
measurement of 1.0 (a point at which the concentration of the antibody in the 
serum is directly proportional to the absorbance). Each data point shows the 
average (± standard deviation) of four interpolated values (one per mouse) for 




Protective Efficacy of mAb 3D11 After Sporozoite Challenge Delivered 
Intravenously versus by Mosquito Bite 
  
Having worked out how to deliver equivalent sporozoite doses after intravenous 
and mosquito bite inoculation, and the optimal time for antibody administration, we 
created an experimental design incorporating these data (Figure 10). We then conducted a 
series of experiments to determine whether passively administered mAb 3D11 had the 
same protective efficacy against sporozoites inoculated intravenously versus by mosquito 
bites. We first investigated this using 50 µg of mAb 3D11 and gave the control groups an 
equivalent amount of mouse serum IgG, henceforth referred to as mIgG. The results for 
two independent experiments are shown in Figure 11A.  In both experiments, we 
observed that 50 µg mAb 3D11 conferred less protection against intravenous challenge 
compared to mosquito bite challenge. However, in both experiments the liver parasite 
burden in our control group receiving 500 P. berghei sporozoites IV was statistically 
significantly higher than that in our control group receiving 8 mosquito bites. This can be 
challenging when interpreting the results, as it is not clear whether the protective effect 
observed in the antibody group is actually due to the antibody or if it is simply a result of 
fewer sporozoites reaching the liver. 
Therefore, we decided to decrease the intravenous inoculum to 250 P. berghei 
sporozoites, hoping that this would allow us to achieve similar parasite liver burdens in 
the control groups, and repeated the experiment using 50 µg mAb 3D11 (Figure 11B). 
Again, we observed the same trend as before, with the antibody being more protective 
against mosquito bite inoculation of sporozoites. However, this time, in two biological 
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replicates, the parasite liver burden in our intravenous control group statistically 
significantly lower than that in our mosquito bite control group. 
To look at our data side by side, we calculated the change in parasite 18s rRNA 
copy number in each treatment group compared to the average of the respective control 
group.  In Figure 12A, these results are shown side-by-side for the four independent 
experiments. The difference in percent reduction between the intravenous and mosquito 
bite groups is statistically significant for each experiment (p<0.001, Mann-Whitney).  
To determine the average percent reduction in the intravenous and mosquito bite 
groups across the four experiments, we pooled the data together (Figure 12B). In the 
groups receiving 50 µg mAb 3D11, compared to their respective controls, we found an 
average reduction in parasite liver burden of 93% in mice challenged by mosquito bite 
and a 69% reduction in mice challenged intravenously. These reductions, compared to the 









Figure 10. A schematic of our experimental design. Briefly, mice are inoculated 
with antibody 24h prior to P. berghei sporozoite challenge either intravenously 
(I.V.) or by mosquito bite (M.B.). 40h later, mice are sacrificed and the liver 







Figure 11. Liver parasite burden in mice passively immunized with 50 µg mAb 
3D11 and then challenged 24h later with: A. 500 intravenously (I.V.) inoculated P. 
berghei sporozoites or 8 mosquito bites (M.B.), and B. 250 intravenously (I.V.) 
inoculated P. berghei sporozoites or 8 mosquito bites (M.B.). Mice were 
sacrificed 40 hours after challenge and liver parasite burden quantified by RT-
qPCR. n=6 mice/group for the first experiment (top-left), and n=5 mice/group for 
the remaining three experiments.  
















Figure 12A.  Percent inhibition in liver parasite burden after passive transfer of 50 
µg mAb 3D11 24h prior to challenge with sporozoites inoculated intravenously 
(I.V.) versus by mosquito bite (M.B.). Two replicates of two different 
experimental protocols are shown. Data are presented as the percent of mean of 
the respective controls. B. Pooled percent reduction in liver parasite burden in 
mice passively immunized with 50 µg mAb 3D11 against intravenous and 
mosquito bite challenge (4 experiments).  






We next wanted to determine whether we would see a similar impact on mosquito 
injected sporozoites with a lower dose of passively administered antibody. Given the 
difficulty to achieve comparable liver parasite burden in our intravenous and mosquito 
bite control groups, we modified the intravenous inoculum to 350 P. berghei sporozoites. 
Using 8 mosquito bites and 350 intravenously inoculated P. berghei sporozoites, we 
performed a series of experiments with 25 µg mAb 3D11 passively administered 24 
hours prior to challenge. We hypothesized that we would observe a reduced level of 
protection in the mAb 3D11 treated groups compared to previous experiments. The 
results for three independent experiments are shown in Figure 13. In all three experiments, 
we can observe a trend consistent with what we saw for 50 µg mAb 3D11 – that the 
antibody is less protective against intravenous inoculation of parasites than against 
mosquito bite. For the first two experiments, we were able to achieve statistically similar 
liver parasite burden in our control groups, however, in the third experiment the 
intravenously inoculated control group had a liver parasite burden that was significantly 
higher than that in the mosquito bite control. 
We then normalized the data for easier comparison by calculating the change in 
parasite 18s rRNA copy number in each treatment group compared to the average of the 
respective control group.  As shown in Figure 14A the difference in the reduction 
between the intravenous and mosquito bite groups is statistically significant for the first 
two experiments (p<0.001, Mann-Whitney), but not significant in the third experiment. 
Despite this non-significance, however, the trend of greater reduction in liver parasitemia 
against mosquito bite holds. We also pooled the data to determine the average percent 
reduction in the intravenous and mosquito bite groups (Figure 14B) and found 
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statistically significant reductions in parasite liver burden of 89% (p<0.001) and 50% 
(p<0.0001) in mice challenged by mosquito bite and intravenously respectively.  
Finally, in order to test the hypothesis that the protective effect we were seeing 
with 50 µg mAb 3D11 was dose-dependent, we compared the pooled percent reduction in 
the 50 µg mAb 3D11 intravenous and mosquito bite groups to the pooled percent 
reduction in the same groups for 25 µg mAb 3D11 (Figure 15). We saw a reduced level 
of protection only in the 3D11 group challenged intravenously (a change in percent 
reduction from 69% to 50%), and this 19% difference is statistically significant 
(p<0.0001). However, for the two antibody concentrations, we saw no statistically 
significant reduction in the level of protection in the 3D11 groups challenged by 












Figure 13A-C. Liver parasite burden in mice passively immunized with 25 µg 
mAb 3D11 and challenged 24h later with 350 intravenously (I.V.) inoculated P. 
berghei sporozoites or 8 infected mosquito bites (M.B.) (3 experiments). Mice 
were sacrificed 40 hours after challenge and liver parasite burden quantified by 
RT-qPCR. n=5 mice/group in all three experiments. ** = significant, p<0.001, ns 










Figure 14A.  Percent reduction in liver parasite burden in mice passively 
immunized with 25 µg mAb 3D11 and challenged 24h later either intravenously 
(I.V.) or by mosquito bite (M.B.) (3 experiments). Data are presented as the 
percent of mean of the respective controls.  B. Pooled percent reduction in liver 
parasite burden in mice passively immunized with 25 µg mAb 3D11 and 
challenged 24h later either intravenously or by mosquito bite (3 experiments). ** 







Figure 15. Comparative efficacy of two doses of mAb 3D11 (50 µg and 25 µg) 
passively administered to female C57BL/6 mice 24h prior to challenge by 
mosquito bite (M.B.) or intravenously (I.V.) inoculated P. berghei sporozoites. 
Results are shown as the percent of mean of the respective controls, and were 
pooled from four independent experiments for 50 µg mAb 3D11, and three 
independent experiments for 25 µg mAb 3D11. The relative percent reduction in 
liver parasite burden is shown in red. *** = significant, p<0.0001, ns = not 





A Novel Method for Studying the Pre-erythrocytic Stages: 
Using the rodent malaria model P. berghei ANKA and the C57BL/6 strain of 
mice we show that 350 sporozoites inoculated intravenously and 8 infected mosquito 
bites result in similar liver parasite burdens. Mosquito bite is the natural route of malaria 
infection in the field, and there has been a growing appreciation regarding the complex 
interplay among innate immunity in the skin, mosquito salivary gland components and 
the malaria parasite. However, a key reason many investigators avoid using mosquito bite 
as the route of parasite inoculation is the inability to precisely estimate the number of 
sporozoites inoculated. Assuming that the liver parasite burden is directly related to the 
number of sporozoites that successfully reach and invade hepatocytes, we established a 
method to standardize the route of infection using parasite liver burden as our endpoint 
measure. The significance of this approach is that it allows for a separation of the impact 
of an intervention, such as passively transferred antibodies, on sporozoites in the 
circulation versus sporozoites in both the circulation and the skin. Hence, this 
methodology provides further insight into the role of the skin phase during the initial 
stages of infection. 
It is worth noting that a key limitation of using our model, while indispensable for 
studying host immunity against the pre-erythrocytic stage, is that it is time and resource 
intensive. Moreover, we note that there can be potential differences from one laboratory 
to another in the quality of mosquito infection, viability of dissected sporozoites, strain of 
mice, and strain of P. berghei used.
60
 Therefore, we recommend that the method we have 
established in this work (350 sporozoites versus 8 mosquito bites) be used as a starting 
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point for optimizing the model in other laboratories. In addition, our methodology may be 
extended to compare the efficacy of treatments against intradermal versus mosquito bite 
inoculation of parasites. Such experiments could potentially provide further insight into 
the potential role of mosquito saliva in modulating host immune responses. 
Interestingly, we found that the liver parasite burden saturates beyond 8 mosquito 
bites (Figure 7A-B). A recent paper by Liehl et al. shows the role of a type one interferon 
(IFN) response in hepatocytes triggered by Plasmodium RNA.
57
 We speculate that this 
could be a parasite-induced phenomenon to either prevent overwhelming the host or 
prevent priming of a strong CD8+ T-cell response (which is an important component of 
host immunity against the liver stages).
59, 63
 However, it is interesting to note that we 
don’t observe a similar saturation in liver parasite burden in response to increasing 
numbers of intravenously inoculated sporozoites. One reason for this discrepancy could 
be that the effectiveness of the hepatocyte innate immune response is dependent on 
gradually increasing numbers of hepatocyte infections. This is in line with work by 
Yamauchi et al. showing that sporozoites leave the dermis in a gradual manner.
35
 It is 
possible that the IFN-dependent innate immune response is overwhelmed by the sudden 
influx of large numbers of intravenously inoculated sporozoites. Nevertheless, we think 
this could be an interesting question to address in future work.  
 
Can antibodies act in the skin?  
The skin is the largest organ of the body and our first defensive barrier against 
many pathogens. Pathogens that are able to make it past the epidermis end up in the 
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dermal layer. It is within this compartment that malaria-causing Plasmodium sp. are 
inoculated by the mosquito. In the past decade or so, there has been a growing 
appreciation of immunity in the skin. Orchestrating this immune response are a diverse 
array of lymphoid cells including resident macrophages (also called Langerhans cells), 
mast cells, resident CD4+ and CD8+ T cells, dendritic cells, innate lymphoid cells, and B 
cells.
50, 51
 In the context of malaria infection and immunity, the dermis is the most 
important layer in the skin. This is because mosquitoes inoculate the majority of their 
parasite inoculum into the dermis.
14, 15, 16, 49
 What is important to note is that of the total 
number of parasites inoculated by the mosquito (a highly variable number, with an 
average of 123 sporozoites but median of 18), only about 20% of the sporozoites exit the 
skin.
18, 49
 Moreover, sporozoites can take up to two hours to exit the skin, leaving in a 
slow trickle from the site of inoculation.
35
 Therefore, from the perspective of vaccine 
immunology, targeting the sporozoites in the dermis, where they are most vulnerable for 
the longest period of time promises to be an effective approach for future malaria 
vaccines. 
Using intravital microscopy, Vanderberg showed that inoculating mice with 320 
µg of mAb 3D11 led to the complete immobilization of sporozoites inoculated by 
mosquito bite into a mouse ear.
47
 Since 320 µg is much higher than what is observed in 
naturally-infected and immunized individuals, we sought to investigate this observation 
using our methodology using lower doses of antibody. We first compared the protective 
efficacy of 50 µg of mAb 3D11 against intravenous and mosquito bite inoculation of 
sporozoites 24 hours after antibody treatment. We selected 24 hours as the time of 
parasite challenge because that was the point at which antibody level in the serum 
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becomes relatively stable (Figure 9). We show that the same dose of antibody is 
significantly more protective against mosquito bite than intravenously inoculated 
sporozoites. These results are similar to findings from another study that compared liver 
infection using mAb 2F6 and rodent parasite Plasmodium yoelii, which show a greater 
inhibition in liver parasitemia (as measured by bioluminescence) against mosquito bite 




Our results emphasize the need for evaluating pre-erythrocytic vaccine candidates, 
specifically ones inducing a strong antibody response, using mosquito bites as the route 
of challenge in order to take potential sporozoite neutralization in the dermis into account. 
Moreover, these evaluations can be enhanced by including intravenously challenged 
treatment groups to determine the potential effect antibodies induced by vaccination may 
have on parasite inhibition in the skin. For instance, in a recent study evaluating the 
efficacy of a genetically-attenuated whole sporozoite vaccine,
48
 the authors challenged 
immunized mice intravenously, and concluded that antibodies were playing a minor role 
in limiting liver infection. Given our results, these conclusions may have missed an 
important component of host immunity against pre-erythrocytic stage of infection. 
The methodology we have established here may also be combined with chimeric 
rodent malaria parasites to allow for the in vivo evaluation of vaccine candidates against 
human Plasmodium parasites, for which we lack suitable animal models. For example, 







 could be challenged using our methodology to gain a more comprehensive 
picture of host immunity against human Plasmodium parasites in vivo. This could help in 
narrowing down promising vaccine candidates for future clinical development. 
Our results of greater antibody-mediated protection against mosquito bite, suggest 
that mAb 3D11 might be acting within the dermis. However, if this is true, how does this 
antibody get there? We looked in the literature for potential candidates among known 
IgG receptors.
55
 There are a number of proteins in the Fc family of receptors that are 
capable of binding IgG antibodies. However, to date, only a single receptor is known to 
bind as well as transport IgG antibodies across cells. This is the neonatal Fc receptor, 
FcRn, and was first discovered in the context of maternal immunity, in its central role in 
the passive transfer of maternal antibodies to the fetus.
52
 In addition, FcRn is also 
responsible for significantly extending the half-life of IgG antibodies in the serum.
52
 
Research on FcRn over the past few decades has primarily focused on its exploitation for 
extending the half-life of drugs by engineering drugs with an Fc region that is specific to 
therapeutic IgG antibodies.
54
 However, in addition to its expression in 
syncytiotrophoblasts, FcRn is also expressed in the lungs, kidneys, and in endothelial 
vessels.
53
 But no one has yet explored the potential role of FcRn in transporting IgG 
antibodies from the vasculature into the dermis. An interesting future avenue to pursue 
could be to investigate whether passively administered mAb 3D11 is as protective against 
mosquito bite in FcRn -/- mice, as we observe in wild type mice.  
In conclusion, we developed a new method to compare the efficacy of an antibody 
after intravenous and mosquito bite inoculation of sporozoites. We then used this method 
to quantitatively show that the dose-dependence for an antibody targeting the malaria 
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parasite is different depending on the route of parasite challenge. This, combined with the 
fact that mosquito bite is the natural route of malaria infection suggests that, despite the 
technical challenges, this may be a superior model for studying the pre-erythrocytic 
stages in rodent models. Therefore, we recommend that future work in rodent malaria 
models, particularly for studying antibody responses against the pre-erythrocytic stages, 
be tested by mosquito bite. Our results support the idea that antibodies acting in the skin 
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